Divis Laboratories Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ho05foxqj8o3jp2wpsm8adkc.pdf

Key Takeaways


The Top-Line Void: Why Management Won't Project

Dr. Murali K. Divi: "I used to project every year 5% to 10% growth year-on-year on the regular business. It is so dynamic situation right now which we are in... it's very difficult to give projections at this moment."

Generic API: Price Pressure Meets a Demand Trough


Custom Synthesis: The Quiet Growth Engine

Dr. Murali K. Divi: "Those who say make in Europe, make in U.S., but there are no big API manufacturing facilities. The maximum they can do is maybe take N minus 1 and finish the APIs for the requirement of only in U.S. or for Europe."

Capacity & Capital Allocation: Flexibility Over Fixed Bets

Dr. Murali K. Divi: "The planning is about in the next 2, 3 years to spend about Rs. 2,000 crore, Rs. 3,000 crore. But if opportunities require, we don't mind spending Rs. 4,000 crore to Rs. 5,000 crore because, we do accumulate and our reserves do permit such expansion."

Margins & The Kaizen Moat

Dr. Murali K. Divi: "If somebody is getting 20% or 30% on a product, we know what to do... where people think that to make a 10% margin is difficult, I can say that we'll make 50% margin in that product."

The Patent Cliff Pipeline & Next-Gen Generics


Guidance & Commitments

CommitmentSpecificsTimeline
Generic demand normalizationDeferred therapeutic segments (anti-infectives, pain, anti-inflammatory) return as hospitals resume surgeries and treatments6 months to 1 year, conditional on pandemic not changing course
Custom synthesis commercial supplyTwo large projects begin commercial volumesNext 1–2 years
Patent-expiry generics supplyCapacity ready, validations in progress for products worth ~$20 bn going off-patentBetween 2023 and 2025, as patents expire
Contrast media improvementMarket share gains driven by iodine cost advantageNext 2–3 years
CAPEX baselineRs. 2,000–3,000 crore spendNext 2–3 years
CAPEX upside scenarioUp to Rs. 4,000–5,000 crore if opportunities requireNo fixed timeline; reserves permit
Kakinada investment startConstruction begins upon government clearanceClearance expected "any day"
Margin floorWork toward 40% base margin; choose products for longevity, not spot marginOngoing

Key Metrics

MetricQ4 FY22
Consolidated total revenue₹2,571 cr, +42% YoY
Consolidated total revenue (FY22)₹9,074 cr, +29% YoY
Profit before tax₹1,076 cr, +61% YoY (Q4)
Profit after tax₹897 cr, +78% YoY (Q4)
EBITDA margin (FY22)44%
Material consumption (FY22)34% to 35% of revenue, based on product mix
Product mix: generics vs custom synthesis (FY22)41% generics, 59% custom synthesis
Nutraceutical business revenue₹157 cr
Exports share (FY22)90% of revenue
Exports to Europe and America (FY22)77% of revenue
Constant currency growth (Q4)39% YoY
FOREX gain₹29 cr
Cash on book₹2,804 cr as of Mar 31, 2022
Receivables₹2,570 cr as of Mar 31, 2022
Inventories₹2,644 cr as of Mar 31, 2022
Networth₹11,691 cr as of Mar 31, 2022
Capitalized assets during the quarter₹172 cr
Capital work in progress₹470 cr
Capacity utilization~80%, varies 80%–85% quarter-on-quarter
Tax rate (FY22)~21%, down from 25% in FY21
CSR spend (FY22)~₹42 cr
CAPEX plan₹2,000–3,000 cr over next 2–3 years; could rise to ₹4,000–5,000 cr if opportunities require
Contrast media segment growth15%–20% YoY
Iodine price$65–$70 per kg, up from $20–$25
Generic API decline in Q4 (ex-nutraceuticals)~25% YoY (per an analyst's math, not confirmed by management)